Evrysdi is a liquid medicine that is taken by mouth or a feeding tube at home, once daily after a meal and at approximately the same time each day. Can be taken with or without food.

Evrysdi helps the body’s Survival of Motor Neuron 2 (SMN2) gene to make more Survival of Motor Neuron (SMN) protein, and taking the medicine consistently helps to maintain these higher SMN levels throughout the body. This increased amount of SMN protein available to motor neurons helps more of them to stay alive, which can lead to improved muscle strength and function in people with SMA. Given the medicine stops muscle weakness and wasting from getting worse, it is important that treatment is started as early as possible.

Your neurologist will advise the best treatment option for you or your child with SMA. 

Evrysdi is available on the Pharmaceutical Benefits Scheme (PBS) for people of all ages with SMA types 1–3 who have SMA symptoms, or people who do not yet have symptoms but do have one, two or three copies of the SMN2 gene.  

‍

As Evrysdi is a specialised medicine that is unlikely to be carried in stock by regular local pharmacies, a home delivery service is available to all patients. By enrolling in the program, the medication will be delivered directly to you, at a convenient time for you. Speak to your healthcare professional for more information and to enrol.

‍

The CMI provides important information about using Evrysdi.